Gilead's $7.8 Billion Arcellx Bid Just Hit a Speed Bump Nobody Expected
The FTC is reviewing Gilead's $7.8 billion acquisition of Arcellx, catching the biotech industry off guard during its biggest M&A boom in years. The scrutiny could reshape how every pharma company approaches dealmaking in 2026.
Biotech dealmakers spent all of 2025 high-fiving each other. M&A was back, baby. Deal values more than doubled. Cash was flowing. And then, like a bouncer checking IDs at the hottest club in town, the FTC stepped in front of Gilead Sciences' $7.8 billion acquisition of Arcellx and said: "Not so fast."
The Federal Trade Commission is reviewing the deal, and the level of scrutiny has caught the industry off guard. This isn't just about one transaction. It's a signal flare for every pharma CEO with an acquisition wish list and a board presentation ready to go.
The Deal That Caught the FTC's Eye
Gilead announced on February 23, 2026, that it would acquire Arcellx through its Kite subsidiary for $115 per share in cash, plus a $5 per share contingent value right (basically a bonus payment if the lead drug hits a sales milestone). The implied equity value: $7.8 billion. That price tag represented a 68-79% premium over where Arcellx shares had been trading, which tells you how badly Gilead wanted this.
And why wouldn't they? Arcellx's crown jewel is anito-cel, a CAR T-cell therapy for multiple myeloma. Think of CAR T as a way to reprogram a patient's own immune cells into cancer-seeking missiles. Those are eye-popping numbers, even by oncology standards. The FDA has a target action date of December 23, 2026, meaning approval could come before the year is out.
Gilead and Arcellx aren't strangers, either. The two companies have been collaborating on anito-cel through Kite since 2022, with Gilead investing hundreds of millions along the way. So this acquisition felt less like a blind date and more like finally putting a ring on it.
Why the FTC Cares About a Cancer Drug
The FTC's antitrust review is zeroing in on several factors: Gilead's preexisting ownership stakes in Arcellx, pipeline overlaps between the two companies, and competition in what regulators call "innovation markets." That last term is key. It means the FTC isn't just looking at drugs already on pharmacy shelves; they're worried about whether this deal could reduce competition for treatments still in development.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
As Associate Dean Daryl Lim noted, partial ownership doesn't get you a free pass under the Hart-Scott-Rodino Act (the law that requires companies to notify regulators before closing big mergers). The FTC focuses on competitive realities in the relevant market, which in this case means: who else is developing BCMA-targeted therapies for multiple myeloma, and does combining Gilead and Arcellx shrink that competitive field too much?
If the FTC decides it needs more information, it could issue a "Second Request," which is essentially the regulatory equivalent of your professor asking you to show all your work. That process can drag a deal timeline out by months.
The Bouncer Has Been Busy Lately
This isn't happening in a vacuum. The FTC has been flexing in healthcare M&A throughout 2025 and into 2026, and the results have been mixed.
In August 2025, the agency challenged Edwards Lifesciences' proposed acquisition of JenaValve, a deal worth $945 million involving heart valve devices. The FTC argued the merger would reduce innovation and competition, obtained a temporary restraining order, and ultimately succeeded in blocking the transaction in January 2026.
But the FTC also took a swing and missed. When it tried to block GTCR's acquisition of Surmodics (a medical device coatings company), a federal court denied the preliminary injunction in November 2025. The judge found flaws in the FTC's market definition, essentially saying the agency had drawn the competitive boundaries too narrowly.
So the scorecard is split: one win, one loss. The Gilead-Arcellx review could be the tiebreaker that tells the industry which direction the wind is really blowing.
A Party Crasher at the M&A Revival
The timing here is what makes this so interesting. Biotech M&A had its best year since 2021, and the momentum was supposed to carry right into 2026.
Consider the numbers: major deals included Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular and Novartis' approximately $12 billion purchase of Avidity.
Analysts were projecting 2026 deal values of $140-160 billion, with some optimistic forecasts reaching $190 billion. The logic was simple: a massive patent cliff is looming (blockbuster drugs losing exclusivity), private biotechs need exit routes, interest rates have come down, and balance sheets are loaded with cash. All the ingredients for a dealmaking feast.
Now the FTC is standing in the kitchen, inspecting the recipe.
The Real Question: Is This a Warning Shot or a New Normal?
The political backdrop makes this harder to read than a typical regulatory cycle. The current FTC leadership under the Trump administration was expected to take a "much more permissive" approach to mergers compared to Lina Khan's aggressive tenure (she stepped down in January 2025). And in many sectors, that's been true.
But healthcare has been the exception. Even under new leadership, the agency has shown it's willing to challenge life sciences deals, particularly when innovation competition is at stake. The Edwards Lifesciences block proved that. The revised Hart-Scott-Rodino thresholds that took effect in 2026 also cast a wider net: deals valued above $133.9 million now require FTC notification, pulling more mid-sized biotech acquisitions into the review pipeline.
For Gilead specifically, the concern centers on Kite's existing position in CAR T-cell therapy. Kite already markets Yescarta and Tecartus, both approved CAR T products. Adding Arcellx's anito-cel would give Gilead a dominant hand in one of oncology's most promising (and expensive) treatment categories. From the FTC's perspective, that concentration is worth a hard look.
What This Means for the Next 12 Months
If you're a biotech CEO shopping for acquisition targets, this review changes your calculus. Not because the deal will necessarily be blocked; the FTC may ultimately clear it. But the uncertainty alone has a chilling effect.
Deal timelines get longer. Legal costs go up. Boards get skittish. And the targets themselves start demanding higher breakup fees to compensate for regulatory risk. Expect contingent value rights and similar mechanisms to remain popular if regulatory unpredictability becomes a feature of the landscape rather than a bug.
The sectors most likely to feel the squeeze are the ones where a handful of companies dominate: cell therapy, gene therapy, antibody-drug conjugates (ADCs), and the red-hot obesity drug market. If you're the third-largest player acquiring the fourth-largest, the FTC is going to want to understand why that's good for patients.
The Bottom Line
Gilead's acquisition of Arcellx still has a reasonable shot at closing, with an expected timeline of Q2 2026. No divestiture requirements have been announced, and no formal challenge has been filed. The FTC review may amount to a thorough look that ends with a green light.
But the message has been sent. Even in a pro-business administration, even in a booming M&A market, even when the deal involves a promising cancer therapy, the FTC is watching. The era of assuming regulatory approval is a rubber stamp? That's over.
For biotech's dealmakers, the game hasn't changed. But the referee just showed everyone that the rulebook still has teeth.
